SUO 2020: Oral HIF-2a Inhibitor MK-6482 for Von Hippel-Lindau (VHL) Disease-Associated Clear Cell Renal Cell Carcinoma: Evaluation of RCC and Non-RCC Disease

(UroToday.com) MK-6482 (aka belzutifan or PT2977), a small-molecule inhibitor of HIF-2α, was tested in a phase II trial presented by Dr. Ramaprasad Srinavasan at the 2020 Society of Urologic Oncology Best of Kidney Cancer poster session.